ライフサイエンスコーパス: clear cell

1 carcinoma histotypes (serous, endometrioid, clear cell).

2 Rlog2 = 1.40 (1.03-1.91)], but not serous or clear cell.

3 d, most notably, two distinct populations of clear cells.

4 microglia respond, microglia are the debris-clearing cell.

5 onents [1.08 serous, 1.11 endometrioid, 1.26 clear cell, 0.94 mucinous].

6 1.17)], endometrioid [1.20 (1.10-1.32)], and clear cell [1.37 (1.18-1.58)], but not mucinous [0.99 (0

7 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other).

8 stoma) and 68 malignant masses (including 41 clear cell, 20 papillary, and seven chromophobe renal ce

9 serous, 319 endometrioid, 184 mucinous, 121 clear cell, 577 other/unknown).

10 Next, syntaxin 6 expression was evaluated in clear cell (786-O and Caki-1) and papillary (Caki-2 and

11 Ovarian clear cell adenocarcinoma (OCCA) is characterized by a p

12 ncanonical signaling by IL6 in human ovarian clear cell adenocarcinoma cell lines and identifies comb

13 Her medical history was significant for clear cell adenocarcinoma of the endometrium.

14 haracteristics (eg, endometrioid, serous, or clear-cell adenocarcinoma).

15 yte nuclear factor 1 homeobox B), markers of clear-cell adenocarcinoma.

16 hereas miR-429 was significantly elevated in clear cell and endometrioid cancer versus controls.

17 marker in ccRCC that can distinguish between clear cell and papillary subtypes.

18 ring by risk factors separated endometrioid, clear cell, and low-grade serous carcinomas from high-gr

19 is-related tumors that include endometrioid, clear cell, and seromucinous carcinomas; ii) low-grade s

20 helial cell types including principal cells, clear cells, and basal cells, along with associated supp

21 Further, we found no mutations typical of clear cell carcinoma (Arid1a, Pik3ca), low-grade serous

22 ack of current treatment options for ovarian clear cell carcinoma (CCC) and the cancer is often resis

23 The Cancer Genome Atlas (TCGA) Kidney Renal Clear Cell Carcinoma (KIRC) dataset (n=114, 906 600 SNPs

24 t invasive carcinoma (BRCA) and kidney renal clear cell carcinoma (KIRC) from The Cancer Genome Atlas

25 sing five genomics datasets for Kidney Renal Clear Cell Carcinoma (KIRC) from The Cancer Genome Atlas

26 Kidney renal clear cell carcinoma (KIRC) is the most common renal cel

27 s are rarely present at diagnosis of ovarian clear cell carcinoma (OCC).

28 In ovarian clear cell carcinoma (OCCC), a challenging subtype of ov

29 Ovarian clear cell carcinoma (OCCC), a very aggressive subtype,

30 r serous (OR = 1.43; 95% CI = 0.82-2.49) and clear cell carcinoma (OR = 2.05; 95% CI = 0.36-11.57; P

31 t associations found were between height and clear cell carcinoma (OR per SD increase: 1.36, 95% CI 1

32 sis, together with RNAseq profiling in renal clear cell carcinoma cases (n=392), to compare immune ge

33 Immune gene expression analysis in the renal clear cell carcinoma cohort showed that the presence of

34 71) and the Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma data set (n=413).

35 alphavbeta3 expression by tumor cells in the clear cell carcinoma group.

36 Concurrent thyroid metastasis of clear cell carcinoma is uncommon but it can appear as a

37 l populations from a patient-derived ovarian clear cell carcinoma model which forms malignant ascites

38 rom The Cancer Genome Atlas program's Kidney Clear Cell Carcinoma project.

39 Clear cell carcinoma showed the strongest genetic correl

40 carcinoma (ccRCC, also known as kidney renal clear cell carcinoma), papillary (pRCC, also known as ki

41 been removed eight years earlier because of clear cell carcinoma.

42 s carcinomas but at low frequency in ovarian clear cell carcinoma.

43 et driving the aggressive phenotype in renal clear cell carcinoma.

44 or suppressor is a hallmark feature of renal clear cell carcinoma.

45 Ovarian clear-cell carcinoma (OCCC) is an aggressive form of ova

46 ependence and specific protein expression in clear-cell carcinoma.

47 The subtypes of RCC were as follows: clear cell carcinomas (n=23), papillary carcinomas (n=6)

48 s and is mutated in more than 50% of ovarian clear cell carcinomas (OCCC), a disease that currently h

49 related with low RARbeta expression in renal clear cell carcinomas and bladder urothelial carcinomas,

50 cy also occurs in poor prognosis endometrial clear cell carcinomas and has some association with endo

51 histotypes (low grade serous, mucinous, and clear cell carcinomas), the inability to directly examin

52 ly, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently have no effective

53 subtypes, including endometrioid, serous and clear cell carcinomas.

54 Clear-cell carcinomas (CCCs) are a histological group of

55 Histopathological diagnosis was renal clear cell carinoma.

56 In particular, clear cells (CCs) secrete protons into the lumen via the

57 erogeneous uptake patterns are observed with clear cell-cell variations in tumor xenograft tissues, n

58 ed or metastatic renal cell carcinoma with a clear-cell component were recruited from 175 hospitals a

59 ically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals a

60 three ccRCC epigenetic clusters, including a clear cell CpG island methylator phenotype (C-CIMP) subg

61 Microglia are the principal phagocytes that clear cell debris in the central nervous system (CNS).

62 Women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer sho

63 cell line categories: epithelial (group I), clear cell (group II) and mesenchymal (group III).

64 ion, but the mechanism for this is still not clear; cells grown in 3D have opportunities to develop i

65 nt-naive, advanced renal cell carcinoma with clear cell histology were enrolled in 129 sites (hospita

66 nd Obstetrics [FIGO] stage I-IIa, grade 3 or clear cell histology) or more advanced disease (FIGO sta

67 58 years, 71% of patients were men, 84% had clear cell histology, 53% were at intermediate risk of r

68 rent or metastatic renal cell carcinoma with clear cell histology, a Karnofsky Performance Status of

69 sease; or stage I-III disease with serous or clear cell histology; were aged 18 years and older; and

70 Mixed tumours with a clear-cell histology component were excluded.

71 atients initiated treatment, of whom 96% had clear-cell histology, 51% were treatment naive, and 67%

72 h common genomic alterations associated with clear-cell histology, we found that Hippo was one of the

73 ll carcinoma on the basis of studies done in clear-cell histology.

74 Key findings were replicated in narrow/clear cells in the epididymis, also part of the MRC fami

75 Proton secretion by epididymal clear cells is achieved via the proton pumping V-ATPase

76 ified through The Cancer Genome Atlas (TCGA) clear cell kidney (KIRC) dataset (419 white and 19 Afric

77 high incidence of mTOR mutations observed in clear cell kidney cancer, where VHL loss and HIF activat

78 Focusing on breast and clear-cell kidney tumors, we report the existence of key

79 tain histotypes of ovarian cancer, including clear cell, low-grade serous and endometrioid carcinomas

80 and Methods Eligible patients had untreated clear cell mRCC and Eastern Cooperative Oncology Group p

81 s and Methods Patients with treatment-naive, clear cell mRCC were treated with four cycles of sunitin

82 Patients with clear-cell mRCC previously treated with agents targeting

83 tiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic t

84 Patients with clear-cell mRCC who progressed on or after vascular endo

85 ession in transgenic mice, resulted in renal clear cells, multi-layered basement membranes, severe cy

86 ific diagnostic and screening biomarkers for clear cell or papillary RCC and in the differential diag

87 noninvasive biomarkers to diagnose malignant clear cell or papillary renal cell carcinoma (RCC) in a

88 ntrolled trial, patients with a component of clear cell or sarcomatoid histology and who were previou

89 (FIGO; 1988) stage IC-IIA high-grade serous, clear cell, or any poorly differentiated or grade 3 hist

90 onfirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence inte

91 2), reduced the proliferation of a subset of clear cell ovarian cancer cell lines in vitro.

92 e III/IV high-grade serous, endometrioid, or clear cell ovarian cancer in clinical complete response

93 g EGLN1 as a potential therapeutic target in clear cell ovarian cancer patients.

94 findings reveal a differential dependency of clear cell ovarian cancers on EGLN1, thus identifying EG

95 helial cells (EECs), the likely precursor of clear cell ovarian carcinomas (CCOCs).

96 enotype of a genomically quiet kidney tumor, clear cell papillary renal cell carcinoma (CCPAP).

97 The mean ER of clear cell, papillary and chromophobe RCC were 188+/-49.

98 The mean WR of clear cell, papillary and chromophobe RCCs were 28.6+/-6

99 glycogen accumulation, and acquisition of a clear cell phenotype in Vhl-deficient renal epithelial c

100 F-1alpha and HIF-2alpha are required for the clear cell phenotype.

101 that glycogen accumulation associated with a clear-cell phenotype in hypoxic cancer cells lacking HIF

102 may provide a treatment for cancers with the clear-cell phenotype.

103 There were many cancer cells with a "clear-cell" phenotype in the HIF1A-deficient tumors; thi

104 r suppressor that is lost in the majority of clear cell RCC (ccRCC) cases.

105 er genes, including VHL, a common initiating clear cell RCC (ccRCC) genetic lesion, and PBRM1 and BAP

106 Clear cell RCC (ccRCC) showed more intense contrast enha

107 reclinical models derived from patients with clear cell RCC (ccRCC) who exhibited primary resistance

108 (FSTL1) was significantly down-regulated in clear cell RCC (ccRCC), in particular metastatic ccRCC.

109 e major RCC histological subtypes, including clear cell RCC (ccRCC), papillary RCC (pRCC) and chromop

110 erations found in human papillary (pRCC) and clear cell RCC (ccRCC), the most common RCC subtypes.

111 demonstrated V2R expression and activity in clear cell RCC (ccRCC).

112 ected cohort of patients with non-metastatic clear cell RCC (the MSK peritumoral adipose tissue cohor

113 ndependent clinical cohorts of patients with clear cell RCC aged 18 years and older.

114 nce in ER (P=0.001) and WR (P=0.001) between clear cell RCC and other subtypes of RCC.

115 s and has markably lower glucose uptake than clear cell RCC and papillary RCC.

116 ns formation were pointed out as a potential clear cell RCC biomarkers.

117 CC cases (the largest cohort to date) and 74 clear cell RCC cases (ccRCC, the most common RCC subtype

118 nt survival advantage in obese patients with clear cell RCC compared with patients at a normal weight

119 The genotype of solid clear cell RCC differed significantly from the genotype

120 sion parameters useful in differentiation of clear cell RCC from chromophobe and papillary RCCs.

121 values of ER and WR used for differentiating clear cell RCC from other subtypes of RCC were 142 and 3

122 Pathological result was reported as clear cell RCC metastasis.

123 th high risk of recurrence, or patients with clear cell RCC only.

124 ogic fidelity, these models of papillary and clear cell RCC should be significant contributions to th

125 tients with advanced (ie, stages III and IV) clear cell RCC treated by nephrectomy; after exclusion o

126 The complex interplay between the clear cell RCC tumour and peritumoral adipose tissue mic

127 Patients with metastatic clear cell RCC who experienced progression after at leas

128 population was 33% and 50% in patients with clear cell RCC with sarcomatoid differentiation and 26%

129 d-lower pole of the left kidney diagnosed as clear cell RCC with vascular invasion, liver, lung and b

130 , KDM5C, and BAP1 were absent in multicystic clear cell RCC, mutations of VHL (P = .016) and PBRM1 (P

131 of these novel manifestations of paediatric clear cell RCC.

132 gnificantly from the genotype of multicystic clear cell RCC.

133 ) were significantly more common among solid clear cell RCC.

134 tients with digital CT images and metastatic clear-cell RCC treated with sunitinib were included (n =

135 The most common subtype (~70% of cases) is clear-cell RCC.

136 nts with high-risk (pT3, pT4, node-positive) clear cell renal cancer (ccRCC) in the ASSURE trial (adj

137 ognised as necessary for the pathogenesis of clear cell renal cancer (ccRCC); however, the molecular

138 etermine the phenotypes of isogenic pairs of clear cell renal cancer cells (ccRCC), with or without V

139 reviously untreated patients with metastatic clear cell renal cancer recruited between June 2008 and

140 reviously untreated patients with metastatic clear cell renal cancer.

141 n patients with intermediate-risk metastatic clear cell renal cancer.

142 XBSeq2 by using a set of in-house generated clear cell renal carcinoma (ccRCC) samples.

143 ed the anti-tumor effect of MLN4924 in human clear cell renal carcinoma (ccRCC).

144 rt a case of a 56-year-old male patient with clear cell renal carcinoma confirmed on a histopathologi

145 Most clear cell renal carcinomas (ccRCCs) are initiated by so

146 s mutated in diverse tumour types, including clear cell renal carcinomas (ccRCCs).

147 e at risk of developing multiple independent clear cell renal carcinomas.

148 Clear cell renal cell carcinoma (CC-RCC) is the most let

149 tandard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of

150 properties in mouse models of CAIX-positive clear cell renal cell carcinoma (ccRCC) and colorectal c

151 immune checkpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and other solid

152 f flux balance analysis in two cancer types, clear cell renal cell carcinoma (ccRCC) and prostate ade

153 tin 3 (TRPM3) channel promotes the growth of clear cell renal cell carcinoma (ccRCC) and stimulates M

154 In this study, we focused on clear cell renal cell carcinoma (ccRCC) and utilized RNA

155 e transcriptomic and epigenomic profiling of clear cell renal cell carcinoma (ccRCC) by The Cancer Ge

156 scular area mask (VAM) in H&E micrographs of clear cell renal cell carcinoma (ccRCC) cases from The C

157 The adipocyte-like morphology of clear cell renal cell carcinoma (ccRCC) cells results fr

158 The presence of sarcomatoid features in clear cell renal cell carcinoma (ccRCC) confers a poor p

159 The genetic landscape of clear cell renal cell carcinoma (ccRCC) had been investi

160 Clear cell renal cell carcinoma (ccRCC) has been previou

161 Although clear cell renal cell carcinoma (ccRCC) has been shown t

162 ysregulation of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncover

163 However, its role in clear cell renal cell carcinoma (ccRCC) has not been des

164 netics of Von Hippel-Lindau (VHL)-associated clear cell renal cell carcinoma (ccRCC) has the potentia

165 Recent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered n

166 The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and p

167 Clear cell renal cell carcinoma (ccRCC) is a gender-bias

168 nd a T cell infiltration score and find that clear cell renal cell carcinoma (ccRCC) is among the hig

169 Clear cell renal cell carcinoma (ccRCC) is an aggressive

170 Clear cell renal cell carcinoma (CCRCC) is an incurable

171 Clear cell renal cell carcinoma (ccRCC) is characterized

172 Clear cell renal cell carcinoma (ccRCC) is characterized

173 Clear cell renal cell carcinoma (ccRCC) is highly hetero

174 Clear cell renal cell carcinoma (ccRCC) is histologicall

175 Clear cell renal cell carcinoma (ccRCC) is the most comm

176 Clear cell renal cell carcinoma (ccRCC) is the most comm

177 Human clear cell renal cell carcinoma (ccRCC) is therapy resis

178 in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and fiv

179 iptional profiling of a cohort of 50 primary clear cell renal cell carcinoma (ccRCC) samples from The

180 1) was revealed to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which w

181 Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromati

182 On the other hand, clear cell renal cell carcinoma (ccRCC) strongly deviate

183 This is particularly true of clear cell renal cell carcinoma (ccRCC) where, although

184 oit novel compounds with high selectivity to clear cell renal cell carcinoma (ccRCC) with common muta

185 genesis is an important prognostic factor of clear cell renal cell carcinoma (ccRCC), as well as a fa

186 In clear cell renal cell carcinoma (ccRCC), AXL expression

187 e has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers

188 In the most common form of RCC, clear cell renal cell carcinoma (ccRCC), inactivation of

189 The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterize

190 1alpha has been termed a tumor-suppressor in clear cell renal cell carcinoma (ccRCC), primarily based

191 Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogeno

192 Clear cell renal cell carcinoma (ccRCC), the most common

193 or gene is the signature initiating event in clear cell renal cell carcinoma (ccRCC), the most common

194 ted as an early event in almost all cases of clear cell renal cell carcinoma (ccRCC), the most freque

195 he deregulated functional modules that drive clear cell renal cell carcinoma (ccRCC), we performed co

196 tumor suppressor and is highly expressed in clear cell renal cell carcinoma (ccRCC), where SLC2A3 ex

197 six tandem BDs and is frequently mutated in clear cell renal cell carcinoma (ccRCC).

198 rface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

199 ection of miR-204 and miR-210 related to the clear cell Renal Cell Carcinoma (ccRCC).

200 xpression was indicative of poor survival in clear cell renal cell carcinoma (ccRCC).

201 major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC).

202 odeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC).

203 genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC).

204 outcomes for African American patients with clear cell renal cell carcinoma (ccRCC).

205 roles in modulating metastasis of VHL-mutant clear cell renal cell carcinoma (ccRCC).

206 dau (VHL) gene mutations are associated with clear cell renal cell carcinoma (ccRCC).

207 ha (HIF-2alpha) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC).

208 inger family, regulates lipid homeostasis in clear cell renal cell carcinoma (ccRCC).

209 rimethyltransferase, have been identified in clear cell renal cell carcinoma (ccRCC); however it is u

210 C is frequently inactivated in patients with clear cell renal cell carcinoma (ccRCC); however, it is

211 ancer subtypes from The Cancer Genome Atlas: clear cell renal cell carcinoma (ccRCC, also known as ki

212 gle-agent targeted therapies in advanced non-clear cell renal cell carcinoma (ncRCC) compared with cl

213 ociated with an increased risk of developing clear cell renal cell carcinoma (RCC) but, paradoxically

214 l renal cell carcinoma (ncRCC) compared with clear cell renal cell carcinoma (RCC) supports the study

215 s in chromosome 8q24.1 (encompassing MYC) in clear cell renal cell carcinoma and chromosome 11q13.3 (

216 se as defined by RECIST 1.1 in patients with clear cell renal cell carcinoma and how the progression

217 pVHL-defective clear cell renal cell carcinoma cell lines display unexp

218 Intriguingly, clear cell renal cell carcinoma cells (ccRCC) have a dys

219 Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification o

220 els of primary and metastatic pVHL-defective clear cell renal cell carcinoma in an on-target fashion.

221 esection between 1998 and 2010 for localised clear cell renal cell carcinoma in the USA).

222 ur recurrence after nephrectomy in localised clear cell renal cell carcinoma is well characterised by

223 om the Cancer Genome Atlas breast cancer and clear cell renal cell carcinoma studies.

224 (Guangzhou, Guangdong, China) with localised clear cell renal cell carcinoma to examine 44 potential

225 with treatment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between Se

226 A total of 361 patients with metastatic clear cell renal cell carcinoma were randomly assigned e

227 of 626 patients from France with stage I-III clear cell renal cell carcinoma who had also undergone n

228 cal outcome in 942 patients with stage I-III clear cell renal cell carcinoma who had undergone a neph

229 papillary, chromophobe, or unclassified non-clear cell renal cell carcinoma with no history of previ

230 ulation by the transcription factor HNF4A in clear cell renal cell carcinoma, despite no differential

231 glioma multiforme, breast, colorectal, skin, clear cell renal cell carcinoma, hepatic and prostate ca

232 linical outcome in patients with stage I-III clear cell renal cell carcinoma, providing a more accura

233 mmune infiltrates in lung adenocarcinoma and clear cell renal cell carcinoma, respectively.

234 In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved prog

235 Clear cell renal cell carcinoma, the most common form of

236 3 and 2014 included patients with metastatic clear cell renal cell carcinoma, with at least one targe

237 sess efficacy of treatments in patients with clear cell renal cell carcinoma.

238 n an attempt to delay disease progression in clear cell renal cell carcinoma.

239 r remains the optimal approach in metastatic clear cell renal cell carcinoma.

240 tor inhibitor sunitinib in patients with non-clear cell renal cell carcinoma.

241 L diseases, including sporadic and inherited clear cell renal cell carcinoma.

242 to improve prediction of recurrence risk in clear cell renal cell carcinoma.

243 eptor inhibitor, in patients with metastatic clear cell renal cell carcinoma.

244 ulation is correlated with YAP activation in clear cell renal cell carcinoma.

245 r infiltrating lymphocytes in the context of clear cell renal cell carcinoma.

246 More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactiv

247 essor gene is inactivated in the majority of clear cell renal cell carcinomas (ccRCC), but genetic ab

248 tumor evolution have been well described for clear cell renal cell carcinomas (ccRCC), but they are l

249 he earliest genetic event in the majority of clear cell renal cell carcinomas (ccRCC), leading to acc

250 VHL-deficient clear cell renal cell carcinomas (ccRCC), the most commo

251 Clear cell renal cell carcinomas (ccRCCs) display diverg

252 Most clear cell renal cell carcinomas (ccRCCs) have inactivat

253 A subset of familial and sporadic clear cell renal cell carcinomas (ccRCCs) is believed to

254 suppressor is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to in

255 ndau (VHL) is a critical tumor suppressor in clear cell renal cell carcinomas (ccRCCs).

256 mors that included renal oncocytomas and non-clear cell renal cell carcinomas (nccRCCs), consisting o

257 Clear cell renal cell carcinomas (RCC) frequently displa

258 Non-clear cell renal cell carcinomas are histologically and

259 tute a significant portion of aggressive non-clear cell renal cell carcinomas that have no standard t

260 usion-weighted MRI may be useful to identify clear cell renal cell carcinomas with higher growth rate

261 Clear-cell renal cell cancer (CRCC) is initiated typical

262 Clear-cell renal cell carcinoma (ccRCC) is a common aggr

263 Importantly, clear-cell renal cell carcinoma (ccRCC) is frequently as

264 n and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models.

265 von Hippel-Lindau (VHL) are major causes of clear-cell renal cell carcinoma (ccRCC) that may origina

266 Clear-cell renal cell carcinoma (ccRCC), the most common

267 cancers caused by VHL inactivation, such as clear-cell renal cell carcinoma (ccRCC).

268 or the development of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC).

269 ad to benign and malignant tumors, including clear-cell renal cell carcinoma (ccRCC).

270 thod to previously published datasets of 100 clear-cell renal cell carcinoma and 99 non-small-cell lu

271 ctivity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised.

272 nd prospective ongoing studies targeting non-clear-cell renal cell carcinoma subtypes and specific mo

273 Of 112 identified patients with non-clear-cell renal cell carcinoma treated at the participa

274 cohort study of patients with metastatic non-clear-cell renal cell carcinoma treated with oral caboza

275 med metastatic or locally advanced (or both) clear-cell renal cell carcinoma were randomly assigned (

276 d patients with histologically confirmed non-clear-cell renal cell carcinoma who received cabozantini

277 years and older with advanced or metastatic clear-cell renal cell carcinoma, measurable disease, and

278 and toxicity of cabozantinib in advanced non-clear-cell renal cell carcinoma.

279 Sarcomatoid clear-cell renal cell carcinomas (sRCC) are associated w

280 tivity and safety of cabozantinib across non-clear-cell renal cell carcinomas.

281 Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor r

282 sphorylated STAT3 are remarkably elevated in clear-cell renal-cell carcinoma relative to adjacent nor

283 ed 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma to receive either suniti

284 rolled patients with advanced or metastatic, clear-cell, renal cell carcinoma.

285 we dissect the molecular mechanisms by which clear cells respond to luminal ATP and adenosine to modu

286 ] per birth, 0.78; 95% CI, 0.74 to 0.83) and clear cell (RR, 0.68; 95% CI, 0.61 to 0.76) carcinomas (

287 5% CI, 1.08 to 1.46) but a decreased risk of clear cell (RR, 0.72; 95% CI, 0.55 to 0.94) tumors (P-he

288 a, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal ca

289 terminus of BCOR in 23 of 27 (85%) pediatric clear cell sarcomas of the kidney (CCSK) from two indepe

290 n were only associated with endometrioid and clear cell tumors (P-het </= .01).

291 We also found that ovarian clear cell tumors susceptible to both genetic and pharma

292 are the most prevalent molecular features of clear cell tumors.

293 irmed a deregulation of CREB1 protein in the clear cell type of RCC (ccRCC) and analysis of in-house

294 nt of metastatic renal cell carcinoma of the clear cell type.

295 Renal cell carcinoma of clear-cell type (ccRCC) is an enigmatic tumor type, char

296 Renal cell carcinoma (RCC) of clear-cell type (ccRCC), the most common type, begins wi

297 The clear cell variant (ccRCC) is the most common and aggres

298 The clear cell variant constitutes a relatively small histol

299 orts an obesity paradox in patients with the clear cell variant; however, population-based cohort dat

300 very unusual, pathologically proven case of clear cell variety of pediatric RCC which showed invasio